Navigation Links
Jennerex and Partners Present Positive JX-594 Randomized Phase 2 Clinical Data Showing Promising Survival Benefit in Patients with Advanced Liver Cancer
Date:5/19/2011

SAN FRANCISCO and SEATTLE, May 19, 2011 /PRNewswire/ -- Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the design, development and commercialization of first-in-class targeted oncolytic products for cancer, today presented preliminary data from a randomized dose-ranging Phase 2 trial of JX-594 in patients with advanced liver cancer showing a benefit in overall survival for the high dose group.  The preliminary data from the study HEP007 indicated that the risk of death for patients who received JX-594 at the high therapeutic dose was markedly reduced by more than 50 percent (hazard ratio < 0.5) when compared to patients randomized to a control low dose (one-tenth of the high dose). Clinical investigators enrolled approximately 30 patients at sites in the United States, Canada and South Korea.

The data were presented by David Kirn, M.D., president and chief executive officer of Jennerex, today in an oral presentation in the Presidential Symposium of the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting in Seattle, Washington.  These data were also chosen for inclusion in ASGCT's Media Event to be held during the annual meeting.  Jennerex and its partners expect to present further follow-up on the complete trial data set at a medical conference later this year.

A randomized, placebo-controlled Phase 2b clinical trial of JX-594 in patients with hepatocellular carcinoma (HCC) having failed sorafenib-(Nexavar®) treatment is planned for initiation in the second half of this year; this trial (TRAVERSE), conducted globally with Jennerex's partners, will evaluate survival in advanced HCC patients who have either progressed or exhibited intolerance after treatment with sorafenib, the current standard of care.

"We are extremely encouraged by the promising overall survival results presented today. These results are consistent with a clinically meaningful survival benefit in patients wit
'/>"/>

SOURCE Jennerex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Jennerex Completes $8.3 Million Series B Financing and Appoints Dr. Cal Stiller as Director
2. Jennerex Appoints Samantha Miller as Vice President of Corporate Development
3. Nature Reviews Publishes Article About Jennerexs Multi-Mechanistic Cancer Therapeutic
4. Jennerex Closes $5 Million First Tranche of Series C Financing
5. Jennerex Completes Over-Subscribed Series C Financing for Aggregate Gross Proceeds of Over $5.5 Million
6. Jennerex Adds Industry Veteran Paul Cleveland to Board of Directors
7. Jennerex Reports Positive Phase 1 Results for JX-594 Administered Intravenously
8. Jennerex Completes Fully Subscribed Private Placement for Aggregate Gross Proceeds of $8.6 Million
9. Jennerex and Transgene Enter Into an Exclusive Partnership for the Development and Commercialization of JX-594 for the Treatment of Cancers
10. Jennerex Appoints James M. Burke, M.D. Vice President, Clinical Research
11. Jennerex to Present JX-594 Liver Cancer Clinical Data at American Society of Gene and Cell Therapy Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... 27, 2015 Research and Markets( http://www.researchandmarkets.com/research/6cg3zw/cell_therapy ... new report "Cell Therapy - Technologies, Markets ... This report describes and evaluates cell therapy technologies ... an important role in the practice of medicine. ... fashioned bone marrow transplants. Role of cells in ...
(Date:5/28/2015)... 28, 2015 DryLet, LLC a ... applications such as animal waste reduction, bioremediation, wastewater ... in wastewater treatment plants and restaurant kitchen settings, ... Pork Expo, June 3-5 in Des Moines, Iowa. ... a Wall Street Journal article because of its ...
(Date:5/28/2015)... , May 28, 2015  GenVec, Inc. (Nasdaq: ... CEO, Douglas J. Swirsky , will present a ... at 11 a.m. EDT on Thursday, June 4, 2015. ... Mr. Swirsky,s presentation will be available at the following ... available on GenVec,s website.  To access, visit www.genvec.com ...
(Date:5/28/2015)... Minneapolis, MN (PRWEB) May 28, 2015 ... makes it a point to ask his audiences ... of future trends including robotics, solar cells, fuel ... sequencing, 3D printers, advanced battery storage technology, driverless ... assistants, and high-quality but inexpensive online education. ...
Breaking Biology Technology:Global Cell Therapy Market 2015-2020 - Technologies, Markets and Companies 2DryLet to Showcase Patented ManureMagicâ„¢ at the 2015 World Pork Expo, June 3-5 in Des Moines, Iowa 2GenVec To Present At The Jefferies Healthcare Conference 2Futurist Jack Uldrich to Deliver 4 Keynote Addresses in June 2
... Corporation,(Nasdaq: CRVL ), a leading provider of ... over 150,000 facility and,provider locations to its national ... new provider network additions are the,result of a ... St. Petersburg, FL. With more than 5,500 ...
... The following statement,was issued today by the law firm of ... that a class action lawsuit was filed in the,United States ... of,all purchasers of securities of LCA-Vision, Inc. (Nasdaq: LCAV ... 30, 2007, inclusive (the,"Class Period"). If you wish to ...
... AviaraDx announced today that,the company,s Carlsbad, CA, ... Pathology (CAP) accreditation. The laboratory offers,two new molecular ... States. CancerTYPE ID(TM) is a 92-gene expression ... ID(TM) provides a molecular classification of metastatic,cancer and ...
Cached Biology Technology:CorVel Corporation Medical Provider Network Adds New Providers to Increase Savings and Improve Access to Care 2CorVel Corporation Medical Provider Network Adds New Providers to Increase Savings and Improve Access to Care 3Shareholder Class Action Filed Against LCA-Vision, Inc. by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP 2Shareholder Class Action Filed Against LCA-Vision, Inc. by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP 3AviaraDx Announces CAP Accreditation of Its Laboratory Operations 2
(Date:5/11/2015)... May 11, 2015 Curemark LLC, a privately ... of a new Phase III double blind, randomized, placebo-controlled ... formulation, CM-AT, on all children ages 3-8 with Autism. ... Phase III double blinded clinical trial for CM-AT in ... of the digestive enzyme chymotrypsin. This new trial will ...
(Date:5/6/2015)... TEL AVIV, Israel , May 6, 2015 /PRNewswire/ ... the world,s most established helmet producer, announced today that ... LifeBEAM Smart Helmet, the world,s first bio-sensing cycling helmet ... will be released in two new colors in order ... demand for the product. In addition, LifeBEAM and Lazer ...
(Date:4/27/2015)... Profile Solutions, Inc. (OTC: PSIQ), a leading ... pleased to announce that Dr Gerry Bedore ... of its scientific advisory board. ... leader in technology-enhanced learning models. He was a co-founder ... studies and books focused on online student success and ...
Breaking Biology News(10 mins):Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4
... of the patients who received injections of steroids contaminated ... Compounding Center has found that some patients had fungal ... of their symptoms and that magnetic resonance imaging (MRI) ... received injections from highly contaminated lots. The ...
... extremely disappointed that the European Chemicals Agency (ECHA) Board ... Benelux B.V.to conduct a pre-natal developmental toxicity study in ... expose pregnant rats and their unborn pups to the ... to comply with the European Community,s Regulation on the ...
... are threatened with extinction as a result of rising human ... Ohio State University in the US. Their work is also ... human population will continue to pose a threat to other ... a threshold above which population growth would cease to have ...
Cached Biology News:Evolution of an outbreak: Complications from contaminated steroid injections 2Are we pushing animals over the edge? 2
...
...
...
... submicron range are part of your production ... of particle size is important to you. ... detect the component populations in your sample ... Analyzer uses Photon Correlation Spectroscopy (PCS) , ...
Biology Products: